30 Aug, 2026 The Power of RNAi for ATTR-CM
body
Alnylam hosted an event at the European Society of Cardiology 2026 congress to discuss the Company’s leadership in TTR, including the strong ongoing launch of AMVUTTRA in ATTR-CM, and the underlying confidence in its next-generation RNAi-powered TTR silencer, nucresiran.
